Safety, Tolerability, and Pharmacokinetics of a Novel Oral Amphotericin B Formulation (iCo-019) following Single-Dose Administration to Healthy Human Subjects: an Alternative Approach to Parenteral Amphotericin B Administration

Documenti analoghi

• Assessing the Safety, Tolerability, Pharmacokinetics, and Biodistribution of Novel Oral Formulations of Amphotericin B following Single- and Multiple-Dose Administration to Beagle Dogs
  di: Wasan, Kishor M., et al.
  Pubblicazione: (2020)
• Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis
  di: Ibrahim, Fady, et al.
  Pubblicazione: (2013)
• Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
  di: Owen David, et al.
  Pubblicazione: (2011-08-01)
• Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
  di: Sivak, Olena, et al.
  Pubblicazione: (2011)
• In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines
  di: Leon, Carlos G, et al.
  Pubblicazione: (2011)